OHSU in the news

In embryos, Crispr can cut out whole chromosomes—that's bad

Wired October 29, 2020
Paula Amato, M.D., and Shoukhrat Mialipov, Ph.D., respond to a Cell paper from Columbia University offering a different explanation for the results shown in their 2017 study demonstrating repair of a genetic mutation in early human embryos.

Genetics and the COVID-19 pandemic

American Society of Human Genetics October 28, 2020
Brendan O’Connell, Ph.D., presented his research, which strongly suggests the primary source of new infections in Oregon are from domestic travel, at theAmerican Society of Human Genetics 2020 Virtual Meeting.

What to do after a dementia diagnosis

Ashland Tidings October 27, 2020
A columnist describes recommendations about how to respond to a dementia diagnosis that she learned while attending a talk by Elizabeth Eckstrom, M.D., M.P.H., and Joe Quinn, M.D.

Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab

Genome & Company October 27, 2020
The OHSU Knight Cancer Institute is one of three clinical trial sites to enroll patients in the first microbiome oncology therapeutic candidate from Genome & Company. Shivaani Kummar, M.D., says “Our goal is to learn more about whether this combination therapy will be effective in overcoming acquired resistance to anti-PD-(L)1 therapy in patients with advanced solid tumors whose disease has progressed on prior anti-PD-(L)1 therapy.”
See more stories